Clinical Trials Directory

Trials / Terminated

TerminatedNCT02633761

Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death

Mifepristone and Misoprostol Versus Misoprostol Alone for Treatment of Fetal Death at 14-28 Weeks of Pregnancy: A Randomized, Placebo-controlled Double-blinded Trial

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Gynuity Health Projects · Academic / Other
Sex
Female
Age
18 Years – 64 Years
Healthy volunteers
Accepted

Summary

The primary aim of this trial is to compare the efficacy of mifepristone-misoprostol versus misoprostol alone for treatment of intrauterine fetal demise between 14 and 28 weeks LMP.

Detailed description

The primary aim of this trial is to compare the efficacy of mifepristone-misoprostol versus misoprostol alone for treatment of intrauterine fetal demise between 14 and 28 weeks LMP. This will be a randomized controlled double-blinded trial of 150 women comparing misoprostol alone to mifepristone plus misoprostol for evacuation of the uterus after fetal demise in the second and third trimester. All women in the trial will undergo routine screening and pre-medical induction care per standard practice at the hospital. All eligible women agreeing to participate in the study will be randomized to receive one of the following regimens: 1. STUDY GROUP ONE: 200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours; 2. STUDY GROUP TWO: placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.

Conditions

Interventions

TypeNameDescription
DRUGMifepristone200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
DRUGPlaceboplacebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
DRUGMisoprostol 200mcgBuccal misoprostol 200mcg

Timeline

Start date
2015-04-01
Primary completion
2018-12-30
Completion
2018-12-30
First posted
2015-12-17
Last updated
2019-02-11

Locations

3 sites across 2 countries: Mexico, Vietnam

Source: ClinicalTrials.gov record NCT02633761. Inclusion in this directory is not an endorsement.